Assefa B, Mahmoud AM, Pfeiffer AFH, Birkenfeld AL, Spranger J, Arafat AM
Whereas much of the current attention surrounding GLP-1 RAs, or glucagon-like peptide-1 receptor agonists, has been focused on their unexpected and potent effect on weight loss, one important aspect of this class of drugs should not be overlooked: GLP-1 RAs have been shown to reduce the risk of heart attack, stroke, and other major adverse cardiovascular events (MACE) in patients with type 2 diabetes who have or are at high risk for atherosclerosis
STEP 1 figure is treatment policy estimand (ITT)
But its not a magic shield
Most people begin to notice subtle improvements in skin hydration and texture within 46 weeks of consistent supplementation
Insurance authorization for the switch may require documentation that semaglutide is no longer effective, which means your provider needs to note the plateau or inadequate response in your medical records